Monophosphoryl Lipid A (S. enterica Minnesota, 595) (VAdv-Ly0011)
| CAT | Size | Price | Quantity | |
|---|---|---|---|---|
| VAdv-Ly0011 |
|
Monophosphoryl Lipid A, derivative from S. enterica Minnesota, 595, a TLR4-based vaccine adjuvant.
Datasheet
Specifications
Type
Lipopolysaccharide
Formula
Monophosphoryl Lipid A from S. minnesota R595
Product Form
White powder
Storage
Store at -20°C.
Shelf Life
1 year
Adjuvant Information
Introduction
Monophosphoryl lipid A (MPLA), derived from the lipid A component of Salmonella minnesota R595 lipopolysaccharide, serves as a TLR4 agonist. Unlike the lipid A region of lipopolysaccharide (LPS), MPLA exhibits lower toxicity and has been shown to elicit a robust Th1 immune response when evaluated in animal models as a vaccine adjuvant. This effect is attributed to its preferential activation of TRIF signaling pathways following TLR4 engagement, leading to diminished production of inflammatory cytokines. MPLA is emerging as a promising vaccine adjuvant and is actively utilized in clinical trials across both preventive and therapeutic vaccine platforms targeting infectious diseases, cancer immunotherapy, and allergen-specific desensitization protocols.
Related Product
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
